4-(trimethylamino)butanoateWhat was measured
Measured, with no finding
71 endpoints
Show what was measuredHide what was measured
free fatty acid concentration in liver
decreases
In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid
PMID 11341370 · one of two readings recorded this
free fatty acid concentration in plasma
no effect
Although the plasma concentrations of FFA in both types of mice were unchanged after administration of gamma-butyrobetaine, the concentrations of palmitic acid and stearic acid were significantly decreased.
PMID 11341370 · one of two readings recorded this
free fatty acid, long-chain fatty acid, palmitic acid and stearic acid concentrations in liver
no effect
whereas those in wild-type mice were not changed
PMID 11341370 · one of two readings recorded this
L-carnitine concentration in brain
increases
levels in the brain, liver and kidney were also significantly increased
PMID 11341370 · one of two readings recorded this
L-carnitine concentration in kidney
increases
levels in the brain, liver and kidney were also significantly increased
PMID 11341370 · one of two readings recorded this
L-carnitine concentration in liver
increases
levels in the brain, liver and kidney were also significantly increased
PMID 11341370 · one of two readings recorded this
L-carnitine concentration in plasma, brain, liver and kidney
no effect
whereas those in wild-type mice hardly changed
PMID 11341370 · one of two readings recorded this
L-carnitine concentration in plasma
increases
After intravenous administration of gamma-butyrobetaine (50 mg kg(-1)), the concentration of L-carnitine in the plasma of JVS mice reached about twice that of the control level
PMID 11341370 · one of two readings recorded this
liver free fatty acid concentration (total FFA, palmitic acid, stearic acid) and plasma and tissue L-carnitine concentration after intravenous gamma-butyrobetaine in juvenile visceral steatosis (JVS) mice
decreases, liver FFA in JVS mice decreased to the wild-type control level
Not recorded as a finding: this platform holds no node for the endpoint
In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid, whereas those in wild-type mice were not changed.
PMID 11341370 · one of two readings recorded this
liver free fatty acid, palmitic acid and stearic acid concentration in JVS mice
decreases, liver FFA in JVS mice decreased to the wild-type control level
Not recorded as a finding: the only sentence reporting it does not name gamma-butyrobetaine (quote not self-supporting); no outcome node for liver free fatty acids
In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid, whereas those in wild-type mice were not changed.
PMID 11341370 · one of two readings recorded this
long-chain fatty acid concentration in liver
decreases
In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid
PMID 11341370 · one of two readings recorded this
palmitic acid concentration in liver
increases
The concentrations of total free fatty acid (FFA), palmitic acid and stearic acid in the liver of JVS mice were significantly higher than those in wild-type mice.
PMID 11341370 · one of two readings recorded this
palmitic acid concentration in liver
decreases
In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid
PMID 11341370 · one of two readings recorded this
palmitic acid concentration in plasma
decreases
Although the plasma concentrations of FFA in both types of mice were unchanged after administration of gamma-butyrobetaine, the concentrations of palmitic acid and stearic acid were significantly decreased.
PMID 11341370 · one of two readings recorded this
stearic acid concentration in liver
increases
The concentrations of total free fatty acid (FFA), palmitic acid and stearic acid in the liver of JVS mice were significantly higher than those in wild-type mice.
PMID 11341370 · one of two readings recorded this
stearic acid concentration in liver
decreases
In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid
PMID 11341370 · one of two readings recorded this
stearic acid concentration in plasma
decreases
Although the plasma concentrations of FFA in both types of mice were unchanged after administration of gamma-butyrobetaine, the concentrations of palmitic acid and stearic acid were significantly decreased.
PMID 11341370 · one of two readings recorded this
total free fatty acid concentration in liver
increases
The concentrations of total free fatty acid (FFA), palmitic acid and stearic acid in the liver of JVS mice were significantly higher than those in wild-type mice.
PMID 11341370 · one of two readings recorded this
inducible nitric oxide synthase inhibition in vitro
no effect
Neither mildronate nor gamma-butyrobetaine could inhibit the inducible nitric oxide synthase in vitro.
PMID 14725614 · one of two readings recorded this
inducible nitric oxide synthase inhibition in vitro
no effect
Neither mildronate nor gamma-butyrobetaine could inhibit the inducible nitric oxide synthase in vitro.
PMID 14725614 · one of two readings recorded this
nitric oxide concentration in all studied tissues
decreases
Its natural analogue gamma-butyrobetaine (30 mg/kg) triggered a twofold decrease of the nitric oxide concentration in all studied tissues 30 min. after the administration.
PMID 14725614 · one of two readings recorded this
nitric oxide concentration in all studied tissues
no effect
Nitric oxide reached the initial level 2 hr later.
PMID 14725614 · one of two readings recorded this
nitric oxide level in blood
increases
in blood from 33.6+/-12.4 to 638+/-136 ng/g tissue
PMID 14725614 · one of two readings recorded this
nitric oxide level in brain cortex and cerebellum
decreases
Administration of the antiischaemic drug, mildronate (120 mg/kg) caused a significant twofold decrease of the nitric oxide level in brain cortex and cerebellum 1 hr after drug administration.
PMID 14725614 · one of two readings recorded this
nitric oxide level in brain cortex
increases
in brain cortex from 46.0+/-3.4 to 227+/-27 ng/g tissue
PMID 14725614 · one of two readings recorded this
nitric oxide level in cerebellum
increases
in cerebellum from 27.7+/-2.6 to 218+/-30 ng/g tissue
PMID 14725614 · one of two readings recorded this
nitric oxide level in heart
increases
in heart from 4.8+/-0.7 to 271+/-26 ng/g tissue
PMID 14725614 · one of two readings recorded this
nitric oxide level in kidney
increases
in kidney from 3.3+/-0.5 to 356+/-31 ng/g tissue
PMID 14725614 · one of two readings recorded this
nitric oxide level in liver
increases
the nitric oxide level in liver of lipopolysaccharide-treated rats increased from 27.6+/-4.7 to 1485+/-129 ng/g tissue
PMID 14725614 · one of two readings recorded this
nitric oxide level in testes
increases
in testes from 13.8+/-1.1 to 86+/-8 ng/g tissue
PMID 14725614 · one of two readings recorded this
tissue nitric oxide level (liver, heart, blood, kidney, brain cortex, cerebellum, testes), electron paramagnetic resonance, in lipopolysaccharide-treated rats
decreases, twofold decrease in all studied tissues 30 min after administration
Not recorded as a finding: no outcome node for tissue nitric oxide concentration; recorded in the mechanism lane as depletes nitric oxide instead
Its natural analogue gamma-butyrobetaine (30 mg/kg) triggered a twofold decrease of the nitric oxide concentration in all studied tissues 30 min. after the administration.
PMID 14725614 · one of two readings recorded this
distribution of radioactivity as L-carnitine in plasma and tissues (tracer dose)
no effect
In an experiment with tracer dose of the compounds, 12 h following administration of [3H]butyrobetaine plasma and tissues contained radioactivity exclusively in L-carnitine and in similar amounts as in the other group of animals receiving L-[3H]carnitine.
PMID 2036448 · one of two readings recorded this
increment in L-carnitine in kidney
increases
kidney, 1227 nmol/g vs. 652 nmol/g
PMID 2036448 · one of two readings recorded this
increment in L-carnitine in liver
increases
liver, 469 nmol/g vs. 258 nmol/g
PMID 2036448 · one of two readings recorded this
increment in L-carnitine in muscle
increases
muscle, 1043 nmol/g vs. 881 nmol/g
PMID 2036448 · one of two readings recorded this
increment in L-carnitine in plasma
increases
plasma, 79.4 nmol/ml vs. 39.3 nmol/ml
PMID 2036448 · one of two readings recorded this
increment in L-carnitine (loading dose)
no effect
Butyrobetaine (100 mumol) caused similar increments when it was administered intraperitoneally.
PMID 2036448 · one of two readings recorded this
increment in L-carnitine (loading dose)
no effect
12 h later it was found that butyrobetaine caused the same increments in L-carnitine as L-carnitine administration
PMID 2036448 · one of two readings recorded this
L-carnitine increments in kidney, liver, muscle (nmol/g) and plasma (nmol/ml) 12 h after oral [3H]butyrobetaine versus L-[3H]carnitine in rats
kidney 1227 vs 652 nmol/g; liver 469 vs 258 nmol/g; muscle 1043 vs 881 nmol/g; plasma 79.4 vs 39.3 nmol/ml
Not recorded as a finding: no outcome node for tissue L-carnitine concentration; the comparator is L-carnitine (active), not absence of the compound
The increments in the organs of the butyrobetaine-treated group (in decreasing order) were as follows: kidney, 1227 nmol/g vs. 652 nmol/g; liver, 469 nmol/g vs. 258 nmol/g; muscle, 1043 nmol/g vs. 881 nmol/g; plasma, 79.4 nmol/ml vs. 39.3 nmol/ml.
PMID 2036448 · one of two readings recorded this
L-carnitine levels in all tissues after a single dose
increases
This work shows that butyrobetaine administered to rats in a single dose can be highly effective in elevating L-carnitine levels in all tissues.
PMID 2036448 · one of two readings recorded this
carnitine after deoxycarnitine administration (matrix not stated, by context urine)
increases
Not recorded as a finding: no outcome node; not recorded as converted_to because the paper attributes the change to tissue exchange between L-carnitine and deoxycarnitine, not conversion
Conversely, administration of deoxycarnitine caused an increase of carnitine.
PMID 2804068 · one of two readings recorded this
carnitine
increases
Conversely, administration of deoxycarnitine caused an increase of carnitine.
PMID 2804068 · one of two readings recorded this
deoxycarnitine concentration in kidney
decreases
Administration of D-carnitine to rats previously loaded with deoxycarnitine significantly depleted the elevated deoxycarnitine concentration in skeletal muscle and kidney while increasing it in plasma.
PMID 2804068 · one of two readings recorded this
deoxycarnitine concentration in plasma
increases
Administration of D-carnitine to rats previously loaded with deoxycarnitine significantly depleted the elevated deoxycarnitine concentration in skeletal muscle and kidney while increasing it in plasma.
PMID 2804068 · one of two readings recorded this
deoxycarnitine concentration in skeletal muscle
decreases
Administration of D-carnitine to rats previously loaded with deoxycarnitine significantly depleted the elevated deoxycarnitine concentration in skeletal muscle and kidney while increasing it in plasma.
PMID 2804068 · one of two readings recorded this
deoxycarnitine in urine
increases
Administration of L-carnitine to rats was followed by an increase of deoxycarnitine in urine.
PMID 2804068 · one of two readings recorded this
L-carnitine concentration in heart, skeletal muscle, kidney, liver and plasma after deoxycarnitine administration
decreases, transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma
Not recorded as a finding: the sentence reporting it says 'The latter treatment' and never names deoxycarnitine (quote not self-supporting); no outcome node for tissue L-carnitine
The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.
PMID 2804068 · one of two readings recorded this
L-carnitine concentration in heart, skeletal muscle, kidney, liver and plasma, and carnitine in urine, after deoxycarnitine administration to rats
decreases, transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, not in liver and plasma
Not recorded as a finding: the supporting sentence never names the compound
The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.
PMID 2804068 · one of two readings recorded this
L-carnitine in heart
decreases
The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.
PMID 2804068 · one of two readings recorded this
L-carnitine in kidney
decreases
The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.
PMID 2804068 · one of two readings recorded this
L-carnitine in liver
no effect
The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.
PMID 2804068 · one of two readings recorded this
L-carnitine in plasma
no effect
The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.
PMID 2804068 · one of two readings recorded this
L-carnitine in skeletal muscle
decreases
The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.
PMID 2804068 · one of two readings recorded this
carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo, and serum and tissue L-carnitine concentrations, in weanling rats fed 1% dietary gamma-butyrobetaine for 32 days
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.
PMID 6619971 · one of two readings recorded this
carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo in rats fed 1% dietary gamma-butyrobetaine for 32 days; also serum and tissue L-carnitine concentrations
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.
PMID 6619971 · one of two readings recorded this
carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo
decreases
Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.
PMID 6619971 · one of two readings recorded this
carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo
decreases
Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.
PMID 6619971 · one of two readings recorded this
carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo
decreases
Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.
PMID 6619971 · one of two readings recorded this
L-carnitine concentration in all tissues studied
increases
Rats fed diets supplemented with L-carnitine (0.1-1.0%) had increased L-carnitine concentrations in serum and all tissues studied.
PMID 6619971 · one of two readings recorded this
L-carnitine concentration in heart
decreases
D-Carnitine (1% of diet) significantly reduced serum and heart L-carnitine concentrations from control levels, and the effects of gamma-butyrobetaine depended on the level of dietary supplementation.
PMID 6619971 · one of two readings recorded this
L-carnitine concentration in serum and tissues
modulates
the effects of gamma-butyrobetaine depended on the level of dietary supplementation
PMID 6619971 · one of two readings recorded this
L-carnitine concentration in serum
decreases
D-Carnitine (1% of diet) significantly reduced serum and heart L-carnitine concentrations from control levels, and the effects of gamma-butyrobetaine depended on the level of dietary supplementation.
PMID 6619971 · one of two readings recorded this
L-carnitine concentration in serum
increases
Rats fed diets supplemented with L-carnitine (0.1-1.0%) had increased L-carnitine concentrations in serum and all tissues studied.
PMID 6619971 · one of two readings recorded this
mean L-carnitine concentration in serum and tissues (except liver)
increases
Mean L-carnitine concentrations in serum and tissues (except liver) from rats fed equivalent amounts of L-carnitine, as the racemic mixture DL-carnitine, were greater than controls but were consistently lower than in rats fed L-carnitine alone.
PMID 6619971 · one of two readings recorded this
mean L-carnitine concentration in serum and tissues (except liver)
decreases
Mean L-carnitine concentrations in serum and tissues (except liver) from rats fed equivalent amounts of L-carnitine, as the racemic mixture DL-carnitine, were greater than controls but were consistently lower than in rats fed L-carnitine alone.
PMID 6619971 · one of two readings recorded this
toxic effects
no effect
Other than mild diarrhea with high levels of some supplements, no toxic effects of these compounds were observed under the conditions employed and within the time frame of the study.
PMID 6619971 · one of two readings recorded this
rate of carnitine biosynthesis (estimated from carnitine excretion)
increases
Ascorbate-supplemented, ascorbate-deficient, and pair-fed (to ascorbate-deficient) animals showed an increase in the rate of carnitine biosynthesis (as estimated from measured rates of carnitine excretion) of 32 to 40 mumol.kg body weight-1.d-1 following supplementation with epsilon-N-trimethyllysine
PMID 7752911 · one of two readings recorded this
rate of carnitine biosynthesis (estimated from carnitine excretion)
increases
Likewise, animals in each experimental group showed an increase in the rate of carnitine biosynthesis of 41 to 50 mumol.kg body weight-1.d-1 after supplementation with gamma-butyrobetaine.
PMID 7752911 · one of two readings recorded this
rate of free and total carnitine excretion
no effect
For guinea pigs not given a carnitine precursor supplement, rates of free and total carnitine excretion for ascorbate-deficient (but not pair-fed) animals were threefold higher than for ascorbate-supplemented animals during days 19 to 28 of the feeding regimen.
PMID 7752911 · one of two readings recorded this
rate of free carnitine excretion
increases
For guinea pigs not given a carnitine precursor supplement, rates of free and total carnitine excretion for ascorbate-deficient (but not pair-fed) animals were threefold higher than for ascorbate-supplemented animals during days 19 to 28 of the feeding regimen.
PMID 7752911 · one of two readings recorded this
rate of total carnitine excretion
increases
For guinea pigs not given a carnitine precursor supplement, rates of free and total carnitine excretion for ascorbate-deficient (but not pair-fed) animals were threefold higher than for ascorbate-supplemented animals during days 19 to 28 of the feeding regimen.
PMID 7752911 · one of two readings recorded this